Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
NCT ID: NCT06873516
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
160 participants
INTERVENTIONAL
2025-03-20
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
NCT06603220
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
NCT04159701
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
NCT02477332
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
NCT07316114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose 1
Orally administered EVO756, dose 1
EVO756
Dose 1
Dose 2
Orally administered EVO756, dose 2
EVO756
Dose 2
Dose 3
Orally administered EVO756, dose 3
EVO756
Dose 3
Placebo control
Orally administered placebo control
Placebo control
Placebo control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EVO756
Dose 3
Placebo control
Placebo control
EVO756
Dose 1
EVO756
Dose 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
* Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
Exclusion Criteria
* Use of certain medications.
* History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
* Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Evommune, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cahaba Dermatology Skin Health Center
Birmingham, Alabama, United States
Velocity Clinical Research, Mobile
Mobile, Alabama, United States
Center for Dermatology Clinical Research
Fremont, California, United States
Antelope Valley Clinical Trials
Lancaster, California, United States
Northridge Clinical Trials
Northridge, California, United States
NorthBay Clinical Research
Santa Rosa, California, United States
Integrated Research of Inland
Upland, California, United States
FOMAT Medical Research
Ventura, California, United States
AMR Fort Myers
Fort Myers, Florida, United States
Advanced Clinical Research Institute
Tampa, Florida, United States
Sneeze, Wheeze & Itch Associates LLC
Normal, Illinois, United States
The Indiana Clinical Trials Center
Plainfield, Indiana, United States
The Iowa Clinic
West Des Moines, Iowa, United States
Hutchinson Clinic
Hutchinson, Kansas, United States
Bluegrass Allergy Care
Lexington, Kentucky, United States
Delricht Research Louisville
Louisville, Kentucky, United States
Delricht Research Louisiana
Baton Rouge, Louisiana, United States
Velocity Clinical Research, Lafayette
Lafayette, Louisiana, United States
Delricht Research
New Orleans, Louisiana, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Boston Specialists
Boston, Massachusetts, United States
MI Skin Innovations
Northville, Michigan, United States
DelRicht Research - Town Center Dermatology
Wildwood, Missouri, United States
Vitality Clinical Trials
Woodbury, New York, United States
Allergy Partners Clinical Research
Asheville, North Carolina, United States
Delricht Research - Priority Care
Charlotte, North Carolina, United States
Piedmont Healthcare
Statesville, North Carolina, United States
Optima Research Boardman
Boardman, Ohio, United States
DOCS Dermatology Research
Canal Winchester, Ohio, United States
Bernstein Clinical Research Center
Cincinnati, Ohio, United States
Toledo Institute of Clinical Research
Toledo, Ohio, United States
AMR Myrtle Beach
Myrtle Beach, South Carolina, United States
National Allergy and Asthma Research
North Charleston, South Carolina, United States
Delricht Research Smyrna
Smyrna, Tennessee, United States
Austin Regional Clinic ARC Clinical Research
Austin, Texas, United States
Studies in Dermatology
Cypress, Texas, United States
Western Sky Medical Research
El Paso, Texas, United States
Delricht Research - Lockhard Matter Dermatology
Prosper, Texas, United States
AMR Utah
Layton, Utah, United States
Seattle Clinical Research Center
Seattle, Washington, United States
Allergy, Asthma, and Sinus Center
Greenfield, Wisconsin, United States
Dandelion Allergy Centre
Mississauga, Ontario, Canada
Allergy Research Canada
Niagara Falls, Ontario, Canada
Red Maple Trials
Ottawa, Ontario, Canada
Centre de Recherche Saint-Louis - Montréal
Montreal, Quebec, Canada
Centre de Recherche Saint-Louis
Québec, Quebec, Canada
Dermatology and Ophthalmology Kume Clinic
Sakai, Osaka, Japan
Yoshikawa Skin Clinic
Takatsuki, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, Japan
Mita Dermatology
Minato-Ku, Tokyo, Japan
ThinkPark Dermatology Clinic
Shinagawa-Ku, Tokyo, Japan
Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
Tachikawa, Tokyo, Japan
Ikebukuro Nishiguchi Fukurou Dermatology
Toshima-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVO756-CSU001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.